Enterovirus A71 antivirals:Past,present,and future  

作　　者：Jun Wang Yanmei Hu Madeleine Zheng 

机构地区：[1]Department of Pharmacology and Toxicology,College of Pharmacy,the University of Arizona,Tucson,AZ 85721,USA

出　　处：《Acta Pharmaceutica Sinica B》2022年第4期1542-1566,共25页药学学报（英文版）

基　　金：This research was supported by the National Institute of Allergy and Infectious Diseasess of Health(NIH,USA,grants AI147325 and AI157046);the Arizona Biomedical Research Commission Centre Young Investigator grant(ADHS18-198859,USA)to Jun Wang;Yanmei Hu was supported by the NIH training grant T32 GM008804(USA).

摘　　要：Enterovirus A71(EV-A71)is a significant human pathogen,especially in children.EV-A71 infection is one of the leading causes of hand,foot,and mouth diseases(HFMD),and can lead to neurological complications such as acute flaccid myelitis(AFM)in severe cases.Although three EV-A71 vaccines are available in China,they are not broadly protective and have reduced efficacy against emerging strains.There is currently no approved antiviral for EV-A71.Significant progress has been made in developing antivirals against EV-A71 by targeting both viral proteins and host factors.However,viral capsid inhibitors and protease inhibitors failed in clinical trials of human rhinovirus infection due to limited efficacy or side effects.This review discusses major discoveries in EV-A71 antiviral development,analyzes the advantages and limitations of each drug target,and highlights the knowledge gaps that need to be addressed to advance the field forward.

关 键 词：Enterovirus A71 EV-A71 AntiviralsAcute flaccid myelitis Hand Foot and mouth disease(HFMD) PICORNAVIRUS 2C protein 

分 类 号：R978.7[医药卫生—药品]